SITC 2021 | SITC clinical practice guidelines on immune checkpoint inhibitor-related adverse events
Whilst immune checkpoint inhibitors (ICIs) have considerably improved patient outcomes in several clinical settings, they are associated with a range of immune-related adverse events (irAEs). Marc S. Ernstoff, MD, National Institutes of Health, Bethesda, MD, gives an overview of the topics covered in the SITC clinical practice guidelines on ICI-related adverse events. These guidelines cover the different organ-specific irAEs observed with ICIs, as well as the levels of toxicity requiring implementation of immunosuppressive treatments, and are designed to educate and assist medical professionals in clinical decision-making. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.
